secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211920
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q1 rev $10.3M; cash $346.7M; Varseta-M dose optimization enrollment complete (40 pts)
--------------------------------------------------------------------------------

- Q1 revenue $10.3M vs $50.9M YoY; decrease driven by completion of BMS and Amgen collaborations.
- Cash $346.7M (Dec 31: $137.1M) includes $234.2M net from March equity offering; runway to at least 2H 2028.
- Varseta-M dose optimization enrollment completed (40 patients); data update in 2H 2026 to inform monotherapy dose and potential registrational trial in late-line CRC.
- Varseta-M + bevacizumab Phase 1 combo underway; initial data by 1H 2027; Phase 1/2 chemo combo starts 2H 2026.
- CX-801 (PROBODY IFNα2b) Phase 1 combo with Keytruda enrolling third dose level; initial combo data expected end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/0001193125-26-211920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526211920/ctmx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer